Oramed Pharmaceuticals (ORMP) FCF Margin (2016 - 2025)

Oramed Pharmaceuticals' FCF Margin history runs 8 years deep, the most recent figure standing at 176.1% for Q1 2025.

• Quarterly FCF Margin changed N/A year-over-year to 176.1% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 457.7% (changed N/A YoY) and the FY2025 annual result came in at 457.7%, changed N/A from the prior year.
• FCF Margin was 176.1% for Q1 2025 at Oramed Pharmaceuticals, up from 393.77% in the prior quarter.
• Across five years, FCF Margin topped out at 176.1% in Q1 2025 and bottomed at 1377.18% in Q1 2022.
• A 4-year average of 721.63% and a median of 645.57% in 2023 frame the typical range for FCF Margin.
• Peak annual rise in FCF Margin reached 86884 bps in 2023, while the deepest fall reached 51411 bps in 2023.
• Oramed Pharmaceuticals' FCF Margin stood at 428.08% in 2021, then plunged by 116 bps to 925.88% in 2022, then surged by 57 bps to 393.77% in 2023, then jumped by 55 bps to 176.1% in 2025.
• Business Quant data shows ORMP's FCF Margin at 176.1% in Q1 2025, 393.77% in Q2 2023, and 863.06% in Q1 2023.